MX343405B - Complejos que emiten alfa-particulas objetivo que comprenden radionuclido de torio e hidroxipiridinona que contiene ligando. - Google Patents

Complejos que emiten alfa-particulas objetivo que comprenden radionuclido de torio e hidroxipiridinona que contiene ligando.

Info

Publication number
MX343405B
MX343405B MX2012009260A MX2012009260A MX343405B MX 343405 B MX343405 B MX 343405B MX 2012009260 A MX2012009260 A MX 2012009260A MX 2012009260 A MX2012009260 A MX 2012009260A MX 343405 B MX343405 B MX 343405B
Authority
MX
Mexico
Prior art keywords
alpha
complexes
tissue
emitting complexes
emitting
Prior art date
Application number
MX2012009260A
Other languages
English (en)
Other versions
MX2012009260A (es
Inventor
Ramdahl Thomas
Original Assignee
Bayer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer As filed Critical Bayer As
Publication of MX2012009260A publication Critical patent/MX2012009260A/es
Publication of MX343405B publication Critical patent/MX343405B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un complejo dirigido a un objetivo de tejido que comprende una porción dirigida a un objetivo de tejido, o un ligando octadentado que contiene hidroxipiridinona, y el ión de un radionúclido alfa-emisor de tono. La invención proporciona adicionalmente métodos terapéuticos que emplean estos complejos, métodos de sub-producción y uso, y kits y composiciones farmacéuticas que comprenden estos complejos.
MX2012009260A 2010-02-12 2011-02-14 Complejos que emiten alfa-particulas objetivo que comprenden radionuclido de torio e hidroxipiridinona que contiene ligando. MX343405B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1002508.8A GB201002508D0 (en) 2010-02-12 2010-02-12 Product
PCT/EP2011/052158 WO2011098611A2 (en) 2010-02-12 2011-02-14 Alpha-emitting complexes

Publications (2)

Publication Number Publication Date
MX2012009260A MX2012009260A (es) 2013-02-07
MX343405B true MX343405B (es) 2016-11-03

Family

ID=42110714

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009260A MX343405B (es) 2010-02-12 2011-02-14 Complejos que emiten alfa-particulas objetivo que comprenden radionuclido de torio e hidroxipiridinona que contiene ligando.

Country Status (26)

Country Link
US (2) US9724436B2 (es)
EP (2) EP2533817B1 (es)
JP (2) JP5878483B2 (es)
KR (1) KR101931382B1 (es)
CN (1) CN103608043B (es)
AU (1) AU2011214281B2 (es)
BR (1) BR112012020304B1 (es)
CA (1) CA2789433C (es)
CY (1) CY1120362T1 (es)
DK (2) DK2533817T3 (es)
EA (1) EA026305B1 (es)
ES (2) ES2794853T3 (es)
GB (1) GB201002508D0 (es)
HR (2) HRP20180996T1 (es)
HU (2) HUE038013T2 (es)
IL (2) IL221416A (es)
LT (2) LT3417883T (es)
MX (1) MX343405B (es)
NZ (1) NZ601867A (es)
PL (2) PL3417883T3 (es)
PT (2) PT3417883T (es)
RS (2) RS60314B1 (es)
SG (1) SG183279A1 (es)
SI (2) SI3417883T1 (es)
TR (1) TR201809149T4 (es)
WO (1) WO2011098611A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2511266B1 (en) 2006-07-10 2019-09-04 The Regents of The University of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
US9273059B2 (en) 2009-08-24 2016-03-01 Lumiphore, Inc. Macrocyclic HOPO chelators
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes
ES2648096T3 (es) 2013-01-14 2017-12-28 Molecular Insight Pharmaceuticals, Inc. Radiofármacos a base de triazina y agentes de radioformación de imágenes
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
GB201310028D0 (en) 2013-06-05 2013-07-17 Algeta Asa Pharmaceutical preparation
MA41176A (fr) * 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
CA2972080A1 (en) * 2014-12-22 2016-06-30 Lumiphore, Inc. Functionalized linear ligands and complexes thereof
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
MX2018011629A (es) 2016-03-24 2019-03-14 Bayer Pharma AG Complejos radiofarmaceuticos.
CR20180581A (es) * 2016-06-10 2019-02-11 Bayer Pharma AG Complejos radio-farmacéuticos
US20200016283A1 (en) 2017-02-24 2020-01-16 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
CN116023429A (zh) 2017-12-13 2023-04-28 塞控斯公司 一种含有与铅或钍放射性核素连接的psma靶向化合物的络合物
EP3843743A1 (en) 2018-08-28 2021-07-07 Bayer AS Combination of pi3k-inhibitors and targeted thorium conjugates
WO2020081174A1 (en) * 2018-10-16 2020-04-23 Nant Holdings Ip, Llc Alpha emitter compositions and methods
EP3927374A1 (en) 2019-02-21 2021-12-29 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
CA3130809A1 (en) 2019-02-22 2020-08-27 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
TW202116733A (zh) 2019-07-25 2021-05-01 挪威商拜耳公司 用於癌症診斷及治療之靶向放射性藥品
MX2023008628A (es) 2021-01-22 2023-09-22 Bayer Ag Anticuerpos lrrc15 y conjugados de los mismos.
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU630362B2 (en) 1988-05-25 1992-10-29 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Macrocyclic chelates & methods of use thereof
DK0429624T3 (da) 1989-06-19 1994-05-30 Akzo Nobel Nv Radioimmunterapi under anvendelse af alfa-partikelemission
SG52470A1 (en) 1992-04-13 1998-09-28 Dow Chemical Co Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
US5624901A (en) 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
ATE266006T1 (de) * 1995-06-14 2004-05-15 Univ California 3-hydroxy-2(1h)-pyridone als chelatbildner
WO1998016254A1 (en) 1996-10-17 1998-04-23 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
US6153596A (en) 1996-12-18 2000-11-28 Emory University Polycationic oligomers
NO310544B1 (no) 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
NO314537B1 (no) 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
WO2001066155A2 (en) 2000-02-25 2001-09-13 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US7893223B2 (en) * 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
GB0213261D0 (en) 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
US20030228256A1 (en) 2002-06-11 2003-12-11 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
US20030086868A1 (en) 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
ITMI20022411A1 (it) 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
KR101274867B1 (ko) * 2003-04-15 2013-06-13 알게타 에이에스 연조직 질환의 방사선 치료에 사용하기 위한 토륨-227
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US20060228297A1 (en) 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease
AU2005215234B2 (en) 2004-02-20 2009-02-19 Algeta As Alpha-emitting Hydroxyapatite particles
CA2570191C (en) * 2004-06-25 2015-04-28 The European Community, Represented By The European Commission Radionuclides for medical use
GB0423565D0 (en) 2004-10-22 2004-11-24 Algeta As Formulation
EP2511266B1 (en) * 2006-07-10 2019-09-04 The Regents of The University of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
EP2423201B1 (en) 2006-08-15 2017-10-04 The Regents of the University of California Luminescent macrocyclic lanthanide complexes
WO2008085064A2 (en) * 2007-01-11 2008-07-17 Ge Healthcare As Hydroxypyridinone chelating agents, their metal complexes and their use as mri contrast agents
WO2011079291A1 (en) * 2009-12-24 2011-06-30 Lumiphore, Inc. Radiopharmaceutical complexes
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201007354D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
GB201007353D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes

Also Published As

Publication number Publication date
CN103608043A (zh) 2014-02-26
PT2533817T (pt) 2018-06-29
RS57360B1 (sr) 2018-08-31
PL3417883T3 (pl) 2020-08-24
TR201809149T4 (tr) 2018-07-23
BR112012020304A2 (pt) 2016-04-26
HRP20200826T1 (hr) 2020-08-07
AU2011214281A1 (en) 2012-08-30
CN103608043B (zh) 2017-07-28
EP3417883A1 (en) 2018-12-26
IL243303A (en) 2017-09-28
DK3417883T3 (da) 2020-06-08
WO2011098611A3 (en) 2015-07-02
GB201002508D0 (en) 2010-03-31
DK2533817T3 (en) 2018-07-16
LT2533817T (lt) 2018-07-10
SI3417883T1 (sl) 2020-07-31
MX2012009260A (es) 2013-02-07
CA2789433A1 (en) 2011-08-18
JP2013519658A (ja) 2013-05-30
IL221416A (en) 2016-03-31
WO2011098611A2 (en) 2011-08-18
CA2789433C (en) 2019-01-15
US10682430B2 (en) 2020-06-16
PT3417883T (pt) 2020-06-01
US9724436B2 (en) 2017-08-08
IL221416A0 (en) 2012-10-31
US20170319721A1 (en) 2017-11-09
EA201290712A1 (ru) 2014-12-30
US20130183235A1 (en) 2013-07-18
JP5878483B2 (ja) 2016-03-08
PL2533817T3 (pl) 2018-08-31
AU2011214281B2 (en) 2014-01-16
KR101931382B1 (ko) 2018-12-20
EP3417883B1 (en) 2020-03-25
NZ601867A (en) 2014-11-28
EP2533817A2 (en) 2012-12-19
HUE038013T2 (hu) 2018-09-28
IL243303A0 (en) 2016-04-21
EP2533817B1 (en) 2018-03-28
EA026305B1 (ru) 2017-03-31
HUE049465T2 (hu) 2020-09-28
RS60314B1 (sr) 2020-07-31
JP2016029114A (ja) 2016-03-03
SG183279A1 (en) 2012-09-27
CY1120362T1 (el) 2019-07-10
ES2674875T3 (es) 2018-07-04
BR112012020304B1 (pt) 2019-12-10
SI2533817T1 (en) 2018-08-31
ES2794853T3 (es) 2020-11-19
HRP20180996T1 (hr) 2018-08-10
KR20120130769A (ko) 2012-12-03
JP6125599B2 (ja) 2017-05-10
LT3417883T (lt) 2020-07-10

Similar Documents

Publication Publication Date Title
MX343405B (es) Complejos que emiten alfa-particulas objetivo que comprenden radionuclido de torio e hidroxipiridinona que contiene ligando.
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
MX2021008976A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
MX2017003886A (es) Conjugado radiofarmaceutico de un metabolito y un agente epr para tratar celulas tumorales.
GB201106750D0 (en) Novel compounds
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
MX2016007826A (es) Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco.
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
EA029818B8 (ru) Цитотоксические и антимитотические соединения и способы их применения
MX2016008448A (es) Conjugados de var2csa-farmaco.
WO2014167126A3 (en) Platform for targeted delivery to stem cells and tumor cells and uses thereof
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX370673B (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
SG182629A1 (en) Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
WO2015040243A3 (en) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
GB201014391D0 (en) Drug composition and its use in therapy
EP3003490A4 (en) Combination therapy for prostate cancer using botanical compositions and docetaxel
MX345263B (es) Formulación de pexiganan estable.
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
EP4233536A3 (en) Method for enhancing tumor growth
MX2012005849A (es) Compuestos inmunomoduladores para la restauracion de la sensibilidad a vitamina d en celulas tumorales resistentes a vitamina d.
TN2012000552A1 (en) An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BAYER AS

FG Grant or registration